|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2014-8-28 10:28 编辑
TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses
Published: Aug 27, 2014 7:30 a.m. ET
MALVERN, Pa., Aug 27, 2014 (GLOBE NEWSWIRE via COMTEX) --
TetraLogic Pharmaceuticals Corporation TLOG, -0.22% today announced that data from the preclinical studies that provide the rationale for SMAC-mimetics as a potential therapy for Hepatitis B will be presented at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses to be held in Los Angeles at UCLA from September 3-6, 2014.
The work has been performed in the laboratory of Dr. Marc Pellegrini, Laboratory Head, Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia and will be presented by Dr. Greg Ebert.
The date and time of the presentations are as follows:
Date & Time: Saturday, September 6, 2014 at 10:45 AM – 12:30 PM (2nd presentation)
Session VIII: Antivirals and New Models
Presentation Title: A potent SMAC-mimetic antagonizes cellular inhibitors of apoptosis and promotes HBV clearance in vivo (the 2nd presentation in Session VIII)
Abstract Number: 0-125
Location: UCLA Conference Facilities
About the Walter and Eliza Hall Institute
The Walter and Eliza Hall Institute is Australia's oldest medical research institute. It is home to almost 750 researchers who are working to understand, prevent and treat diseases including infectious diseases, cancers and immune disorders. It is located in Parkville, Melbourne, and is closely associated with The University of Melbourne and The Royal Melbourne Hospital.
About Birinapant
Birinapant (TL32711) is a potent, bivalent SMAC mimetic that binds with differential affinity to multiple members of the IAP family including cIAP1, cIAP2, XIAP, and ML-IAP. Birinapant is differentiated from other SMAC mimetics in that it results in the selective degradation of cIAP1 bound to TRAF-2 in the TNF receptor complex, sparing non-TRAF-2 bound cIAP2. This unique IAP antagonism profile of birinapant may result in the improved tolerability and therapeutic index observed with this agent.
About TetraLogic
TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid phenyl ester (SHAPE). Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also entering a P1b/2a clinical trial in Hepatitis B. SHAPE is entering Phase 2 trials for early-stage CTCL.
|
|
发表于 2014-8-28 10:25
